Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Cash & Current Investments: 2017-2025

Historic Cash & Current Investments for Puma Biotechnology (PBYI) over the last 9 years, with Sep 2025 value amounting to $94.4 million.

  • Puma Biotechnology's Cash & Current Investments fell 2.42% to $94.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $384.5 million, marking a year-over-year decrease of 3.05%. This contributed to the annual value of $101.0 million for FY2024, which is 5.24% up from last year.
  • Latest data reveals that Puma Biotechnology reported Cash & Current Investments of $94.4 million as of Q3 2025, which was down 1.70% from $96.0 million recorded in Q2 2025.
  • Puma Biotechnology's Cash & Current Investments' 5-year high stood at $109.1 million during Q1 2021, with a 5-year trough of $60.8 million in Q2 2022.
  • For the 3-year period, Puma Biotechnology's Cash & Current Investments averaged around $92.0 million, with its median value being $95.9 million (2023).
  • Per our database at Business Quant, Puma Biotechnology's Cash & Current Investments crashed by 44.25% in 2022 and then surged by 50.47% in 2024.
  • Quarterly analysis of 5 years shows Puma Biotechnology's Cash & Current Investments stood at $82.1 million in 2021, then dropped by 1.26% to $81.1 million in 2022, then increased by 18.34% to $95.9 million in 2023, then increased by 5.24% to $101.0 million in 2024, then declined by 2.42% to $94.4 million in 2025.
  • Its Cash & Current Investments was $94.4 million in Q3 2025, compared to $96.0 million in Q2 2025 and $93.2 million in Q1 2025.